Financials data is unavailable for this security.
View more
Year on year Shanghai Haohai Biological Technology Co Ltd grew revenues 25.27% from 2.10bn to 2.63bn while net income improved 130.58% from 180.47m to 416.12m.
| Gross margin | 70.07% |
|---|---|
| Net profit margin | 15.45% |
| Operating margin | 19.50% |
| Return on assets | 5.81% |
|---|---|
| Return on equity | 7.83% |
| Return on investment | 6.86% |
More ▼
Cash flow in CNYView more
In 2023, Shanghai Haohai Biological Technology Co Ltd did not generate a significant amount of cash. However, the company earned 634.45m from its operations for a Cash Flow Margin of 24.08%. In addition the company used 376.65m on investing activities and also paid 257.73m in financing cash flows.
| Cash flow per share | 3.28 |
|---|---|
| Price/Cash flow per share | 24.17 |
| Book value per share | 26.18 |
|---|---|
| Tangible book value per share | 21.51 |
More ▼
Balance sheet in CNYView more
| Current ratio | 4.60 |
|---|---|
| Quick ratio | 3.98 |
| Total debt/total equity | 0.0746 |
|---|---|
| Total debt/total capital | 0.0655 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 156.30% and 134.67%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Medical Equipment & Supplies industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is above the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
| Div yield(5 year avg) | 1.69% |
|---|---|
| Div growth rate (5 year) | 14.22% |
| Payout ratio (TTM) | 58.28% |
| EPS growth(5 years) | -1.19 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 71.76 |
More ▼
